Best Researcher Award
| Bosco Paes |
| Affiliation |
McMaster University |
| Country |
Canada |
| Scopus ID |
35460184000 |
| Documents |
232 |
| Citations |
8,787 |
| h-index |
46 |
| Subject Area |
Medicine and Health Sciences |
| Event |
Computer Scientists Awards |
Bosco Paes
McMaster University, Canada
Bosco Paes is a Canadian physician-scientist and academic whose research has significantly contributed to neonatal medicine, respiratory syncytial virus (RSV) prevention, neonatal infectious diseases, and evidence-based pediatric healthcare. His scholarly record demonstrates sustained contributions through multicenter clinical studies, systematic reviews, health economic analyses, and international collaborations. With an extensive publication portfolio, substantial citation impact, and an h-index reflecting consistent scientific influence, his research continues to support advances in neonatal clinical practice and healthcare policy.[1]
Abstract
The academic achievements of Bosco Paes demonstrate sustained excellence in pediatric and neonatal medicine, particularly in the prevention and management of respiratory syncytial virus infections among vulnerable infant populations. His investigations integrate clinical medicine, systematic evidence synthesis, and health economics to improve patient outcomes and healthcare resource utilization. Through collaborations with international experts, his publications have influenced preventive strategies and contributed to the scientific understanding of RSV prophylaxis, neonatal intensive care, and pediatric infectious diseases.[2]
Keywords
Neonatology, Pediatrics, Respiratory Syncytial Virus, RSV Prophylaxis, Palivizumab, Nirsevimab, Neonatal Medicine, Health Economics, Systematic Review, Evidence-Based Medicine.
Introduction
Research in neonatal healthcare requires multidisciplinary collaboration and rigorous evaluation of preventive interventions. Bosco Paes has contributed extensively to this field by combining clinical expertise with population-based research and economic evaluations. His work addresses clinically important issues affecting premature infants and supports informed healthcare decisions through robust scientific evidence.[3]
Research Profile
Bosco Paes has authored more than 230 indexed scholarly documents and accumulated nearly nine thousand citations according to Scopus metrics. His research spans neonatal intensive care, pediatric infectious diseases, RSV immunoprophylaxis, epidemiology, health services research, and evidence synthesis. The consistency of his scientific productivity demonstrates long-term engagement in internationally recognized clinical research programs.[1]
Research Contributions
His recent scholarly work includes evaluations of risk factor-guided RSV prophylaxis in Colombian preterm infants, comparative meta-analyses assessing palivizumab and nirsevimab effectiveness, and expert consensus recommendations through the ARMADA Taskforce. These studies integrate clinical evidence with economic analyses and international consensus to improve preventive pediatric healthcare.[4]
Publications
- Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants. Cost Effectiveness and Resource Allocation, 2026.
- Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants. Human Vaccines & Immunotherapeutics, 2026.
- Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA Taskforce, 2026.
Research Impact
The research output of Bosco Paes has informed neonatal clinical practice, preventive immunization strategies, and evidence-based healthcare policies internationally. His collaborations with clinicians, epidemiologists, and health economists have strengthened the translation of scientific findings into practical recommendations for high-risk infant populations. The citation record and publication consistency indicate substantial scholarly influence within pediatric medicine.[5]
Award Suitability
Bosco Paes demonstrates the characteristics commonly associated with distinguished research recognition through sustained scholarly productivity, international collaborations, measurable citation impact, and contributions to neonatal healthcare. His work exemplifies rigorous clinical investigation, interdisciplinary cooperation, and the practical application of scientific evidence for improving patient care, making him a suitable candidate for consideration under the Best Researcher Award category.[6]
Conclusion
The academic profile of Bosco Paes reflects sustained excellence in pediatric and neonatal research with particular emphasis on respiratory syncytial virus prevention and neonatal healthcare. His publication record, collaborative research activities, and measurable scientific impact illustrate meaningful contributions to medical science and evidence-based clinical practice. Collectively, these achievements support recognition within international academic award programs dedicated to research excellence.[1]
External Links
References
- Elsevier. (n.d.). Scopus author details: Bosco Paes, Author ID 35460184000. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=35460184000
- Rodríguez-Martínez CE, Ordóñez JE, Carbonell-Estrany X, Tarride JE, Paes BA. (2026). Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.
https://doi.org/10.1186/s12962-026-00001-0
- Fullarton JR, Paes BA, Waghorne N, et al. (2026). Meta-analysis of the efficacy of palivizumab versus nirsevimab.
- Manzoni P, Baraldi E, Midulla F, et al. (2026). ARMADA Taskforce Systematic Review and Expert Consensus on RSV Prevention.
- Computer Scientists Awards. Best Researcher Award evaluation framework.
https://computerscientists.net/